EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review

Nguyen, Janet; Popović, Marko; Chow, Edward; Cella, David; Beaumont, Jennifer L.; Chu, Dominic; DiGiovanni, Julia; Lam, Henry; Pulenzas, Natalie; Bottomley, Andrew

doi:10.2217/cer.14.76

Cited by 87 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A primary weakness of this study is a lack of another validated measure of physical symptom burden, as opposed to measures such as the Edmonton Symptom Assessment System or the Functional Assessment of Cancer Therapy‐Breast Cancer, which have been validated as patient‐reported outcome measures . Also, stage and length of time with breast cancer and whether they were currently undergoing treatment were not captured and may have provided more information on the timing of when symptoms arise.…”

Section: Study Limitationsmentioning

confidence: 99%

Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Study Limitationsmentioning

confidence: 99%

Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Two additional questions are used to determine the state of health on a seven point Likert scale [33]. The side-effects of therapy and tumor-related symptoms in breast cancer patients were determined and recorded using the additional QLQ-BR23 module, which consists of 23 questions distributed across eight four point scales (in both questionnaires: 1 = not at all; 4 = very much) [34]. The generic EQ-5D-5L questionnaire investigated the quality of life across five question categories using a five point scale and the EQ-VAS scale on which the overall state of health is marked by the patient in the form of a number (0 = worst imaginable state of health, 100 = best imaginable state of health) [35].…”

Section: Questionnairesmentioning

confidence: 99%

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Wallwiener

Simoes

Sokolov

et al. 2016

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Einleitung: Liegt bei einer Krebserkrankung bereits ein fortgeschrittenes Stadium vor und ist somit eine primäre Heilung nicht mehr möglich, steht die Erhaltung der Lebensqualität im Fokus. Gerade beim Mammakarzinom sind durch die verbesserten neuen Therapien auch im metastasierten Stadium noch längere stabile Verläufe möglich. Ziel dieser Studie war es deshalb, einerseits die Lebensqualität der Patientinnen durch einen Vergleich mit Daten der Gesamtbevölkerung darzustellen und andererseits Unterschiede zwischen den verschiedenen Erhebungsinstrumenten aufzuzeigen. Material und Methoden: Insgesamt wurden n = 96 Brustkrebspatientinnen in metastasierter oder adjuvanter Situation hinsichtlich ihrer Lebensqualität befragt. Dabei kamen die etablierten Erhebungsinstrumente EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5L und EQ-VAS zum Einsatz, wobei alle Patientinnen alle Bögen ausfüllten. Die statistische Analyse erfolgte mittels MS Excel und SPSS. Ergebnisse: Obwohl die Bögen zum gleichen Zeitpunkt ausgefüllt wurden, zeigten sich deutliche Unterschiede im Belastungsniveau in Abhängigkeit zum angewandten Bogen. Beim Einsatz des EQ VAS wurde der aktuelle Gesundheitsstatus signifikant besser beurteilt als beim EORTC QLQ-C30. Insgesamt gestaltete sich die Lebensqualität der Patientinnen in allen Dimensionen als optimierungsbedürftig und war in allen Bereichen signifikant schlechter als in der Referenzbevölkerung. Schlussfolgerung: Um die Lebensqualität von metastasierten Patientinnen zu verbessern, ergibt sich die die Notwendigkeit des beständigen Therapieerfolg-Monitorings. Von Relevanz ist die Wahl des Erhebungsinstruments, da in Abhängigkeit vom Erhebungsinstrument unterschiedliche Werte ermittelt wurden.

show abstract

“…As seen in Table , we identified 22 domains to form the basis of our guide. These ranged from health‐related QOL, a very general measure that can be used for patients with multiple cancer sites and stages; to lymphedema, which often is used specifically with patients who have undergone breast surgery; to financial toxicity, a recently identified domain with which to assess the financial and resource‐related difficulties experienced by patients with cancer.…”

Section: Resultsmentioning

confidence: 99%

Patient‐reported outcomes in the Translational Breast Cancer Research Consortium

Bowen

Shinn

Gregrowski

et al. 2019

Cancer

View full text Add to dashboard Cite

Members of the Translational Breast Cancer Research Consortium conducted an expert‐driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer‐reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient‐reported outcomes in relevant patients.

show abstract

EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review

Abstract: Overall, both questionnaires are effective in assessing breast cancer-specific quality of life. Clear similarities and differences between the two tools exist. Decision-making between the questionnaires should be based on the purpose and design of the study.

Cited by 87 publications

References 24 publications

Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer

Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer

Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

Patient‐reported outcomes in the Translational Breast Cancer Research Consortium

Contact Info

Product

Resources

About